Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Therapy Name||Azacitidine + Hu5F9-G4|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Azacitidine||Vidaza||azacytidine|CC-486|5-azacytidine|5-AC|U-18496||DNMT inhibitor (Pan) 5||Vidaza (azacitidine) is a cytidine analog that incorporates into DNA and RNA and binds to DNA methyltransferases (DNMTs), resulting in DNMT degradation and decreased DNA methylation, and leading to increased tumor cell death (PMID: 28159832, PMID: 28067760). Vidaza (azacitidine) is FDA-approved for use in patients with some subtypes of myelodysplastic syndrome (FDA.gov).|
|Hu5F9-G4||Magrolimab||CD47 Antibody 13 Immune Checkpoint Inhibitor 94||Magrolimab (Hu5F9-G4) is a humanized monoclonal antibody against CD47 that binds to and blocks CD47 downstream signaling and subsequent activation of the SIRPa receptor on macrophages, leading to phagocytosis of tumor cells (PMID: 26390038, PMID: 28286286) and may also stimulate cytotoxic T-cells (PMID: 29873856).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Unknown unknown||myelodysplastic syndrome||not applicable||Azacitidine + Hu5F9-G4||Phase I||Actionable||In a Phase Ib trial, Magrolimab (Hu5F9-G4) and Vidaza (azacitidine) combination therapy was well tolerated, and resulted in complete response in 42% (14/33), marrow complete response in 24% (8/33), partial response in 3% (1/33), hematologic improvement in 21% (7/33), and stable disease in 9% (3/33) of patients with intermediate to very high risk myelodyaplastic syndrome (J Clin Oncol 38: 2020 (suppl; abstr 7507); NCT03248479).||detail...|
|Unknown unknown||acute myeloid leukemia||not applicable||Azacitidine + Hu5F9-G4||Phase I||Actionable||In a Phase Ib trial, Magrolimab (Hu5F9-G4) and Vidaza (azacitidine) combination therapy was well tolerated, and resulted in complete response in 40% (10/25), complete response with incomplete hematologic recovery in 16% (4/25), partial response in 4% (1/25), morphologic leukemia-free state in 4% (1/25), and stable disease in 32% (8/25) of patients with acute myeloid leukemia unfit for chemotherapy (J Clin Oncol 38: 2020 (suppl; abstr 7507); NCT03248479).||detail...|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status|
|NCT03248479||Phase I||Azacitidine + Hu5F9-G4 Hu5F9-G4||Hu5F9-G4 Monotherapy or Hu5F9-G4 in Combination With Azacitidine in Patients With Hematological Malignancies||Recruiting|